Antibody therapy could fight second-most deadly strain of virus
Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola. A different strain, the Zaire ebolavirus (EBOV), is now devastating West Africa. First identified in 1976, SUDV has caused numerous Ebola outbreaks (most recently in 2012) that have killed more than 400 people in total. The findings were reported in ACS Chemical Biology.
Between 30 and 90 percent of people infected with Ebola die after experiencing symptoms of the disease that include fever, muscle aches, vomiting and bleeding. In the current EBOV outbreak, at least 1,500 people have died as of the end of August.
Two U.S. aid workers infected in that outbreak received an experimental treatment called ZMapp, a combination of three different monoclonal antibodies that bind to the protein of the virus. The newly described SUDV treatment also uses monoclonal antibodies, in this case synthetic antibodies designed to target a key molecule on the surface of SUDV called the envelope glycoprotein. (A glycoprotein molecule consists of carbohydrates plus a protein).
"While our antibodies show promise for treatment of SUDV infection, they wouldn't work against the EBOV outbreak now underway in West Africa," said Jonathan Lai, Ph.D., associate professor of biochemistry at Einstein and co-corresponding author of the ACS Chemical Biology paper. "That's because antibodies that kill off one strain, or species, of Ebola haven't proven effective against other strains."
In developing their SUDV therapy, the researchers started with specific antibodies made by mice. These antibodies protect the animals against SUDV infection by binding to the envelope glycoprotein on the surface of the virus. But if used in humans, mouse antibodies could provoke an immune response that would destroy them. Needing a "humanized" version of their mouse antibody, the researchers realized that its molecular structure closely resembled the structure of a commonly used human antibody.
The researchers used that human antibody as a scaffold onto which they placed the Ebola-specific portion of the mouse antibody. They then made variants of the resulting molecule by subtly changing its structure in different ways using a process called "synthetic antibody engineering". Two of these variants proved able to fend off SUDV in specially bred mice. "These two monoclonal antibodies represent potential candidates for treating SUDV infection," said Dr. Lai. He noted that more research is needed before the antibody therapy can be tested on humans.
The study, titled "Synthetic Antibodies with a Human Framework that Protect Mice from Lethal Sudan Ebolavirus Challenge," was published online in ACS Chemical Biology on August 20, 2014. In addition to Dr. Lai, other co-corresponding authors were John M. Dye, Ph.D., of the United States Army Medical Research Institute of Infectious Diseases, and Sachdev S. Sidhu, Ph.D., of the University of Toronto. Other Einstein authors were Jayne Koellhoffer, B.S., Julia Frei, B.S., Nina Liu, and Kartik Chandran, Ph.D. Additional authors are Gang Chen, Ph.D., Hua Long, Wei Ye, B.Sc., Kaajal Nagar, and Guohua Pan, Ph.D., all of University of Toronto, and Samantha Zak of the U.S. Army.
The study was funded by grants from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (AI090249, AI088027 and AI09762), the Canadian Institutes for Health Research (MOP-93725) and the Defense Threat Reduction Agency.
About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2013-2014 academic year, Einstein is home to 743 M.D. students, 275 Ph.D. students, 103 students in the combined M.D./Ph.D. program, and 313 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2013, Einstein received more than $150 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center –- Einstein’s founding hospital, and three other hospital systems in the Bronx, Brooklyn and on Long Island, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
Kim Newman | Eurek Alert!
Surprising similarity in fly and mouse motion vision
30.07.2015 | Max Planck Institute of Neurobiology, Martinsried
Intracellular microlasers could allow precise labeling of a trillion individual cells
30.07.2015 | Massachusetts General Hospital
Physicists from Regensburg and Marburg, Germany have succeeded in taking a slow-motion movie of speeding electrons in a solid driven by a strong light wave. In the process, they have unraveled a novel quantum phenomenon, which will be reported in the forthcoming edition of Nature.
The advent of ever faster electronics featuring clock rates up to the multiple-gigahertz range has revolutionized our day-to-day life. Researchers and...
Researchers have developed an ultrafast light-emitting device that can flip on and off 90 billion times a second and could form the basis of optical computing.
Joint BioEnergy Institute study identifies bacterial protein that is key to protecting rice against bacterial blight
A bacterial signal that when recognized by rice plants enables the plants to resist a devastating blight disease has been identified by a multi-national team...
Researchers in the Cockrell School of Engineering at The University of Texas at Austin are one step closer to delivering smart windows with a new level of energy efficiency, engineering materials that allow windows to reveal light without transferring heat and, conversely, to block light while allowing heat transmission, as described in two new research papers.
By allowing indoor occupants to more precisely control the energy and sunlight passing through a window, the new materials could significantly reduce costs for...
Argonne scientists used Mira to identify and improve a new mechanism for eliminating friction, which fed into the development of a hybrid material that exhibited superlubricity at the macroscale for the first time. Argonne Leadership Computing Facility (ALCF) researchers helped enable the groundbreaking simulations by overcoming a performance bottleneck that doubled the speed of the team's code.
While reviewing the simulation results of a promising new lubricant material, Argonne researcher Sanket Deshmukh stumbled upon a phenomenon that had never been...
23.07.2015 | Event News
10.07.2015 | Event News
25.06.2015 | Event News
30.07.2015 | Life Sciences
30.07.2015 | Trade Fair News
30.07.2015 | Awards Funding